SCHEMBL6094441

SCHEMBL6094441

NS(=O)(=O)n1cnc2c(Oc3ccccc3)nccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.40
CA2 P00918 6/20 0.40
CA9 Q16790 5/20 0.40
CA12 O43570 4/20 0.40
HTR6 P50406 2/20 0.39
RPS6KA5 O75582 1/20 0.39
ALDH1A1 P00352 3/20 0.37
SOS1 Q07889 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
HPGD P15428 2/20 0.34
IKBKB O14920 1/20 0.33
CA7 P43166 1/20 0.33
CA13 Q8N1Q1 1/20 0.33
MAPK8 P45983 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4794110 0.76 RPS6KA5 (0.40) RPS6KA5ALDH1A1MEN1KMT2ACYP1A2
SCHEMBL7096192 0.74 LMNA (0.40) CA1CA2CA9CA12ALDH1A1
SCHEMBL6096608 0.73 AHCY (0.43) HTR6
SCHEMBL4793894 0.71 TDP1 (0.42) RPS6KA5ALDH1A1MEN1KMT2ACYP1A2
SCHEMBL4708692 0.66 CA1 (0.50) CA1CA2CA9CA12ALDH1A1
SCHEMBL830432 0.65 ALDH3A1 (0.57) ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL7678752 0.62 MET (0.37) CA1CA2CA9MEN1KMT2A
Diphenylether SCHEMBL28109377 0.62 CA1 (0.71) CA1CA2CA9CA12ALDH1A1
SCHEMBL843417 0.61 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ACYP1A2CYP2C9
SCHEMBL11217950 0.60 ALDH1A1 (0.45) ALDH1A1MEN1KMT2ACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098221-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-08-29 US disclosed
US-20050282854-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2005-12-22 US disclosed
US-6969722-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-11-29 US disclosed
US-6903113-B2 Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-07 US disclosed
US-6878719-B2 Sulfonamido substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-04-12 US disclosed
US-20040186128-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-23 US disclosed
EP-1453829-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-08 EP disclosed
EP-1451186-A2 UREA SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-01 EP disclosed
EP-1451187-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-01 EP disclosed
US-20040157879-A1 Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-08-12 US disclosed
US-20030195209-A1 Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-16 US disclosed
US-20030186949-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-02 US disclosed
US-20030176458-A1 Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-09-18 US disclosed
US-20030162806-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-28 US disclosed
WO-2003050117-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
WO-2003050119-A2 UREA SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
WO-2003050118-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
US-6545017-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 US disclosed
US-6545016-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 US disclosed
US-6525064-B1 Immune response modifiers; can induce the biosynthesis of various cytokines; 3M INNOVATIVE PROPERTIES COMPANY 2003-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186128-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG CA1 4256/4885CA2 3331/4885CA9 3916/4885
US-20030176458-A1 Urea substituted imidazopyridines EIF2AK2, UMPS, IRF3 CA1 4642/4885CA2 4192/4885CA9 4130/4885
US-20030195209-A1 Urea substituted imidazopyridines EIF2AK2, UMPS, IRF3 CA1 4642/4885CA2 4192/4885CA9 4130/4885
US-20050282854-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG CA1 4256/4885CA2 3331/4885CA9 3916/4885
US-20040157879-A1 Urea substituted imidazopyridines EIF2AK2, UMPS, IRF3 CA1 4642/4885CA2 4192/4885CA9 4130/4885
US-20030162806-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG CA1 4256/4885CA2 3331/4885CA9 3916/4885
US-20030186949-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG CA1 4256/4885CA2 3331/4885CA9 3916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.